CN102292328A - 具有cb2受体激动活性的n-取代饱和杂环砜化合物 - Google Patents
具有cb2受体激动活性的n-取代饱和杂环砜化合物 Download PDFInfo
- Publication number
- CN102292328A CN102292328A CN2010800053579A CN201080005357A CN102292328A CN 102292328 A CN102292328 A CN 102292328A CN 2010800053579 A CN2010800053579 A CN 2010800053579A CN 201080005357 A CN201080005357 A CN 201080005357A CN 102292328 A CN102292328 A CN 102292328A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- methyl
- imidazoles
- benzo
- neo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)(C)Cc1nc(cc(cc2)S(C*3CNC3)(=O)=O)c2[n]1CC1CC1 Chemical compound CC(C)(C)Cc1nc(cc(cc2)S(C*3CNC3)(=O)=O)c2[n]1CC1CC1 0.000 description 3
- ABCYUXNFQBVAKJ-UHFFFAOYSA-N CC(C)(C)Cc1nc(cc(cc2)Br)c2[n]1CC1(CCOCC1)O Chemical compound CC(C)(C)Cc1nc(cc(cc2)Br)c2[n]1CC1(CCOCC1)O ABCYUXNFQBVAKJ-UHFFFAOYSA-N 0.000 description 1
- BWRKAQPIBKYKKK-UHFFFAOYSA-N CC(C)(C)Cc1nc(cc(cc2)Br)c2[n]1CC1CC1 Chemical compound CC(C)(C)Cc1nc(cc(cc2)Br)c2[n]1CC1CC1 BWRKAQPIBKYKKK-UHFFFAOYSA-N 0.000 description 1
- DXHZPEUGSBHTJD-UHFFFAOYSA-N CC(C)(C)Cc1nc(cc(cc2)S(C(CC3)CCN3C(OC(C)(C)C)=O)(=O)=O)c2[n]1CC1CC1 Chemical compound CC(C)(C)Cc1nc(cc(cc2)S(C(CC3)CCN3C(OC(C)(C)C)=O)(=O)=O)c2[n]1CC1CC1 DXHZPEUGSBHTJD-UHFFFAOYSA-N 0.000 description 1
- OHLYQKMORVNETR-UHFFFAOYSA-N CC(C)(C)Cc1nc(cc(cc2)S(C3CCNCC3)(=O)=O)c2[n]1CC1CC1 Chemical compound CC(C)(C)Cc1nc(cc(cc2)S(C3CCNCC3)(=O)=O)c2[n]1CC1CC1 OHLYQKMORVNETR-UHFFFAOYSA-N 0.000 description 1
- ADEFVPBXBREFNF-UHFFFAOYSA-N CC(C)(C)Cc1nc(cc(cc2)S(C3CNC3)(=O)=O)c2[n]1CCOC(F)(F)F Chemical compound CC(C)(C)Cc1nc(cc(cc2)S(C3CNC3)(=O)=O)c2[n]1CCOC(F)(F)F ADEFVPBXBREFNF-UHFFFAOYSA-N 0.000 description 1
- ZWMWKFRUFQASKF-UHFFFAOYSA-N CC(C)(C)Cc1nc(cc(cc2)S(CC(C3)CN3C(N)=O)(=O)=O)c2[n]1CC1CC1 Chemical compound CC(C)(C)Cc1nc(cc(cc2)S(CC(C3)CN3C(N)=O)(=O)=O)c2[n]1CC1CC1 ZWMWKFRUFQASKF-UHFFFAOYSA-N 0.000 description 1
- OLCKTBHSPVXUHR-UHFFFAOYSA-N CC(C)(C)Cc1nc(cc(cc2)S(CC(C3)CN3C(OC(C)(C)C)=O)(=O)=O)c2[n]1CC1CC1 Chemical compound CC(C)(C)Cc1nc(cc(cc2)S(CC(C3)CN3C(OC(C)(C)C)=O)(=O)=O)c2[n]1CC1CC1 OLCKTBHSPVXUHR-UHFFFAOYSA-N 0.000 description 1
- VSGBGHBRBPWOSS-UHFFFAOYSA-N CC(C)(C)Cc1nc(cc(cc2)S(CC(CC3)CCN3C(c3c[nH]nc3)=O)(=O)=O)c2[n]1CCN(C)C Chemical compound CC(C)(C)Cc1nc(cc(cc2)S(CC(CC3)CCN3C(c3c[nH]nc3)=O)(=O)=O)c2[n]1CCN(C)C VSGBGHBRBPWOSS-UHFFFAOYSA-N 0.000 description 1
- YUXBCSUJGDPKOJ-UHFFFAOYSA-N CC(C)(C)Cc1nc(cc(cc2)S(CC3CCNCC3)(=O)=O)c2[n]1CCN(C)C Chemical compound CC(C)(C)Cc1nc(cc(cc2)S(CC3CCNCC3)(=O)=O)c2[n]1CCN(C)C YUXBCSUJGDPKOJ-UHFFFAOYSA-N 0.000 description 1
- KFLQBCXRCDCKGJ-UHFFFAOYSA-N CC(C)(C)Cc1nc(cc(cc2)SCC(CC3)CCN3C(OC(C)(C)C)=O)c2[n]1CCN(C)C Chemical compound CC(C)(C)Cc1nc(cc(cc2)SCC(CC3)CCN3C(OC(C)(C)C)=O)c2[n]1CCN(C)C KFLQBCXRCDCKGJ-UHFFFAOYSA-N 0.000 description 1
- USYCVFFWCMHPPG-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1S)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1S)=O USYCVFFWCMHPPG-UHFFFAOYSA-N 0.000 description 1
- SJAKIGKVIJINMY-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1SC(C)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1SC(C)=O)=O SJAKIGKVIJINMY-UHFFFAOYSA-N 0.000 description 1
- UQEANKGXXSENNF-UHFFFAOYSA-N [O-][N+](c1cc(Br)ccc1F)=O Chemical compound [O-][N+](c1cc(Br)ccc1F)=O UQEANKGXXSENNF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20203609P | 2009-01-22 | 2009-01-22 | |
US61/202,036 | 2009-01-22 | ||
US21397709P | 2009-08-04 | 2009-08-04 | |
US61/213,977 | 2009-08-04 | ||
PCT/JP2010/000377 WO2010084767A1 (en) | 2009-01-22 | 2010-01-22 | N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102292328A true CN102292328A (zh) | 2011-12-21 |
Family
ID=42355822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800053579A Pending CN102292328A (zh) | 2009-01-22 | 2010-01-22 | 具有cb2受体激动活性的n-取代饱和杂环砜化合物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8653063B2 (ru) |
EP (1) | EP2379533A4 (ru) |
JP (1) | JP5816883B2 (ru) |
KR (1) | KR20110117146A (ru) |
CN (1) | CN102292328A (ru) |
BR (1) | BRPI1007202A2 (ru) |
CA (1) | CA2747801A1 (ru) |
MX (1) | MX2011007663A (ru) |
RU (1) | RU2011134868A (ru) |
WO (1) | WO2010084767A1 (ru) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102432514A (zh) * | 2011-12-26 | 2012-05-02 | 兰州博实生化科技有限责任公司 | 1-叔丁氧羰基-3-氟氮杂环丁烷的合成方法 |
CN116322672A (zh) * | 2020-11-12 | 2023-06-23 | 株式会社AskAt | 2-[3-({1-[2-(二甲基氨基)乙基]-2-(2,2-二甲基丙基)-1h-1,3-苯并二氮唑-5-基}磺酰基)氮杂环丁烷-1-基]乙-1-醇的稳定盐和晶型 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
WO2012090179A2 (en) | 2010-12-30 | 2012-07-05 | Lupin Limited | Isoquinoline derivatives as cannabinoid receptor modulators |
WO2012090177A2 (en) | 2010-12-30 | 2012-07-05 | Lupin Limited | Cannabinoid receptor modulators |
CN102276511A (zh) * | 2011-06-20 | 2011-12-14 | 兰州博实生化科技有限责任公司 | 1-叔丁氧羰基-3-碘氮杂环丁烷的合成方法 |
WO2013005168A2 (en) | 2011-07-05 | 2013-01-10 | Lupin Limited | Cannabinoid receptor modulators |
US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
JP6499077B2 (ja) | 2012-10-25 | 2019-04-10 | ザ ジェネラル ホスピタル コーポレイション | アルツハイマー病と関連疾患の治療のための併用療法 |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
CN110305095A (zh) * | 2013-10-22 | 2019-10-08 | 综合医院公司 | 色甘酸衍生物以及成像和治疗的相关方法 |
JP2019524865A (ja) | 2016-08-31 | 2019-09-05 | ザ ジェネラル ホスピタル コーポレイション | 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア |
AU2017423862A1 (en) | 2017-07-20 | 2020-02-06 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and ibuprofen |
JP2021529771A (ja) | 2018-07-02 | 2021-11-04 | ザ ジェネラル ホスピタル コーポレイション | クロモリンナトリウムおよびα−ラクトースの粉末製剤 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1703402A (zh) * | 2002-09-27 | 2005-11-30 | 葛兰素集团有限公司 | 用作cb2受体调节剂的吡啶衍生物 |
WO2006048754A1 (en) * | 2004-11-02 | 2006-05-11 | Pfizer Japan Inc. | Sulfonyl benzimidazole derivatives |
WO2007102059A1 (en) * | 2006-03-06 | 2007-09-13 | Pfizer Japan Inc. | Sulfonyl benzimidazole derivatives |
WO2008003665A1 (en) * | 2006-07-04 | 2008-01-10 | Janssen Pharmaceutica Nv | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2751649B1 (fr) * | 1996-07-26 | 1998-08-28 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US8193369B2 (en) | 2007-03-30 | 2012-06-05 | Janssen Pharmaceutica Nv | Benzimidazole cannabinoid agonists |
WO2009077533A1 (en) * | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica Nv | Fluoroalkyl substituted benzimidazole cannabinoid agonists |
-
2010
- 2010-01-22 MX MX2011007663A patent/MX2011007663A/es not_active Application Discontinuation
- 2010-01-22 CN CN2010800053579A patent/CN102292328A/zh active Pending
- 2010-01-22 BR BRPI1007202A patent/BRPI1007202A2/pt not_active IP Right Cessation
- 2010-01-22 CA CA2747801A patent/CA2747801A1/en not_active Abandoned
- 2010-01-22 WO PCT/JP2010/000377 patent/WO2010084767A1/en active Application Filing
- 2010-01-22 EP EP10733374A patent/EP2379533A4/en not_active Withdrawn
- 2010-01-22 US US13/145,439 patent/US8653063B2/en active Active
- 2010-01-22 RU RU2011134868/04A patent/RU2011134868A/ru unknown
- 2010-01-22 JP JP2011526737A patent/JP5816883B2/ja active Active
- 2010-01-22 KR KR1020117018693A patent/KR20110117146A/ko not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1703402A (zh) * | 2002-09-27 | 2005-11-30 | 葛兰素集团有限公司 | 用作cb2受体调节剂的吡啶衍生物 |
WO2006048754A1 (en) * | 2004-11-02 | 2006-05-11 | Pfizer Japan Inc. | Sulfonyl benzimidazole derivatives |
WO2007102059A1 (en) * | 2006-03-06 | 2007-09-13 | Pfizer Japan Inc. | Sulfonyl benzimidazole derivatives |
WO2008003665A1 (en) * | 2006-07-04 | 2008-01-10 | Janssen Pharmaceutica Nv | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
Non-Patent Citations (1)
Title |
---|
BIE M.P. VERBIST, ET AL,: ""5-Sulfonyl-benzimidazoles as selective CB2 agonists"", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102432514A (zh) * | 2011-12-26 | 2012-05-02 | 兰州博实生化科技有限责任公司 | 1-叔丁氧羰基-3-氟氮杂环丁烷的合成方法 |
CN102432514B (zh) * | 2011-12-26 | 2014-05-07 | 兰州博实生化科技有限责任公司 | 1-叔丁氧羰基-3-氟氮杂环丁烷的合成方法 |
CN116322672A (zh) * | 2020-11-12 | 2023-06-23 | 株式会社AskAt | 2-[3-({1-[2-(二甲基氨基)乙基]-2-(2,2-二甲基丙基)-1h-1,3-苯并二氮唑-5-基}磺酰基)氮杂环丁烷-1-基]乙-1-醇的稳定盐和晶型 |
CN116322672B (zh) * | 2020-11-12 | 2024-04-09 | 株式会社AskAt | 2-[3-({1-[2-(二甲基氨基)乙基]-2-(2,2-二甲基丙基)-1h-1,3-苯并二氮唑-5-基}磺酰基)氮杂环丁烷-1-基]乙-1-醇的稳定盐和晶型 |
Also Published As
Publication number | Publication date |
---|---|
BRPI1007202A2 (pt) | 2016-02-23 |
EP2379533A4 (en) | 2012-07-04 |
JP2012515712A (ja) | 2012-07-12 |
RU2011134868A (ru) | 2013-02-27 |
US20110281840A1 (en) | 2011-11-17 |
WO2010084767A1 (en) | 2010-07-29 |
US8653063B2 (en) | 2014-02-18 |
EP2379533A1 (en) | 2011-10-26 |
KR20110117146A (ko) | 2011-10-26 |
MX2011007663A (es) | 2011-08-15 |
CA2747801A1 (en) | 2010-07-29 |
JP5816883B2 (ja) | 2015-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102292328A (zh) | 具有cb2受体激动活性的n-取代饱和杂环砜化合物 | |
AU2020274011B2 (en) | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | |
ES2609258T3 (es) | Derivados de bencimidazol | |
CN100482659C (zh) | 具有5-ht4受体激动活性的苯并咪唑酮化合物 | |
CN105263935B (zh) | 6,7‑二氢吡唑并[1,5‑a]吡嗪‑4(5H)‑酮化合物及其作为MGLUR2受体的负性别构调节物的用途 | |
CN104379575B (zh) | 用于调节egfr活性的化合物和组合物 | |
KR101985050B1 (ko) | 피라진카르복사미드 화합물 | |
ES2434337T3 (es) | Derivados de azabiciclo[3.1.0]hexilo como moduladores de los receptores D3 de la dopamina | |
JP6378759B2 (ja) | Sumo活性化酵素阻害剤として有用なヘテロアリール化合物 | |
CN108137590A (zh) | 作为mdm2-p53抑制剂的新的螺(3h-吲哚-3,2′-吡咯烷)-2(1h)-酮化合物及其衍生物 | |
BR112016010041A2 (pt) | composto, medicamento, e, uso do composto ou sal | |
JP2009503050A (ja) | ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物 | |
WO2020210828A1 (en) | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions | |
RU2528406C2 (ru) | Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в | |
CN101522668A (zh) | 作为5-ht4受体激动剂的羟基吲哚衍生物 | |
JP2008543824A (ja) | アシッドポンプアンタゴニストとしてのクロマン置換ベンゾイミダゾール誘導体 | |
CN102321077A (zh) | 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途 | |
TW200813022A (en) | Organic compounds | |
US9765056B2 (en) | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | |
CN105189480A (zh) | 在治疗由IKKε和/或TBK-1机制介导的疾病中有用的嘧啶化合物 | |
JP2009541463A (ja) | ピペリジンまたはピロリジンの尿素誘導体、これらの調製およびこれらの治療的使用 | |
JP2008533121A (ja) | Cb2受容体リガンドとしてのベンズイミダゾロン誘導体 | |
TW201736367A (zh) | 6,7,8,9-四氫-5H-吡啶并[2,3-d]氮呯多巴胺D3配體 | |
CN107072993A (zh) | 含有钠依赖性磷酸转运蛋白抑制剂的药物 | |
CN101528750B (zh) | 作为选择性酸泵抑制剂的苯并咪唑衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1164294 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111221 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1164294 Country of ref document: HK |